It was not until the financial year 2004/2005 that all patients with Haemophilia A, of whatever age, had access to recombinant Factor 8. Read more about It was not until the financial year 2004/2005 that all patients with Haemophilia A, of whatever age, had access to recombinant Factor 8.
Individuals were still experiencing issues with equal access to recombinant Factor 8 as a result of funding. Read more about Individuals were still experiencing issues with equal access to recombinant Factor 8 as a result of funding.
By this date it had been confirmed that in Northern Ireland recombinant Factor 8 would be funded for all patients. Read more about By this date it had been confirmed that in Northern Ireland recombinant Factor 8 would be funded for all patients.
By this date all patients with Haemophilia in Scotland were being treated with recombinant Factor 8 or 9. Read more about By this date all patients with Haemophilia in Scotland were being treated with recombinant Factor 8 or 9.
Charles Lister wrote to Nick Raisen regarding synthetic blood products. Read more about Charles Lister wrote to Nick Raisen regarding synthetic blood products.
Recombinant Factor 9 was licensed and the funding arrangements in England mirrored those for Factor 8. Read more about Recombinant Factor 9 was licensed and the funding arrangements in England mirrored those for Factor 8.
Pete Longstaff refused human derived Factor 8 products in a treatment strike which lasted until his death. Read more about Pete Longstaff refused human derived Factor 8 products in a treatment strike which lasted until his death.
Bruce Norval described writing to the Secretary of State "to try and make sure that kids got on to recombinant products as early as possible". Read more about Bruce Norval described writing to the Secretary of State "to try and make sure that kids got on to recombinant products as early as possible".
At a meeting of the UKHCDO Executive Committee Dr Ludlam said that Charles Lister had "again informally indicated that funding for [Factor 8] should continue beyond the 16th birthday." Read more about At a meeting of the UKHCDO Executive Committee Dr Ludlam said that Charles Lister had "again informally indicated that funding for [Factor 8] should continue beyond the 16th birthday."
The Secretary of State agreed to the central funding for 1998/1999 of recombinant Factor VIII for new patients and those under 16. This was on what were described as humanitarian (rather than effectiveness grounds). Read more about The Secretary of State agreed to the central funding for 1998/1999 of recombinant Factor VIII for new patients and those under 16. This was on what were described as humanitarian (rather than effectiveness grounds).